Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
Linepharma’s combination pack of mifepristone and misoprostol tablets, the first abortion pills to hit the Japan market if approved, was endorsed by a key health ministry panel on January 27. With a great deal of attention being drawn to the…
To read the full story
Related Article
- Japan Approves Mefeego as First Abortion Pill
May 1, 2023
- Health Ministry Panel OKs Japan’s First Abortion Pill with Official Go-Ahead Set for May
April 24, 2023
- Abortion Pill Mefeego’s Japan Panel Review Rescheduled for April 21
April 18, 2023
- Lawmakers Split 50/50 on Abortion Pill, No Conclusion at LDP Panel
April 13, 2023
- Public Comments 2 to 1 in Favor of Approving Abortion Pill: MHLW
March 27, 2023
- Review of Abortion Pill Postponed amid Flock of Public Comments
March 24, 2023
- Oral Abortion Pill Mefeego Up for Another Round of Panel Reviews on March 24
March 20, 2023
- OB/GYN Group Urges MHLW to Facilitate Access to Oral Abortion Drug
February 24, 2023
- Semaglutide in Line for March Approval as Obesity Drug, Precedex Too
January 30, 2023
- Linepharma Submits NDA for Abortion Pills in Japan
December 23, 2021
REGULATORY
- LDP Project Team Flags Drug Pricing as Key to Investment
March 19, 2026
- Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
March 18, 2026
- MHLW Seeks Industry Survey on Petroleum-Linked Products amid Iran Crisis
March 18, 2026
- MHLW Orders Label Revisions for Antiepileptics and Other Drugs
March 18, 2026
- MHLW Panel OKs Draft Criteria for “Specified Medical Technologies”
March 17, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…